Literature DB >> 879736

Synergistic action of erythromycin and cefamandole against Bacteroides fragilis subsp. fragilis.

R S Griffith, G L Brier, J D Wolny.   

Abstract

Erythromycin and cefamandole have exhibited synergistic activity against eight strains of Bacteroides fragilis subsp. fragilis. In concentrations of only 0.25 to 0.5 mug of erythromycin per ml (easily obtainable with oral therapy), less than 0.4 mug (0.015 to 1.0) of cefamandole per ml inhibited the B. fragilis strains. In the presence of the erythromycin, the potency of cefamandole was increased more than 100-fold. On the basis of the mechanism of action of these two antibiotics, the synergism may be related to inhibition of beta-lactamase formation by the erythromycin, removal of the bacterial cell wall by the cefamandole permitting erythromycin penetration to the ribosomal level, and decreasing inoculum effect.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 879736      PMCID: PMC352080          DOI: 10.1128/AAC.11.5.813

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  A comparison of blood levels after oral administration of erythromycin and erythromycin estolate.

Authors:  R S GRIFFITH; H R BLACK
Journal:  Antibiot Chemother (Northfield)       Date:  1962-06

2.  Identification and antimicrobial susceptibility of 250 Bacteriodes fragilis subspecies tested by broth microdilution methods.

Authors:  R N Jones; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

3.  Dispensing Apparatus for Controlling E(h), pH, and Volume of Anaerobic Bacterial and Protozoal Culture Media.

Authors:  P P Williams
Journal:  Appl Microbiol       Date:  1966-11

4.  Microdilution technique for antimicrobial susceptibility testing of anaerobic bacteria.

Authors:  C A Rotilie; R J Fass; R B Prior; R L Perkins
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

5.  Simple method for culturing anaerobes.

Authors:  C E Davis; W J Hunter; J L Ryan; A I Braude
Journal:  Appl Microbiol       Date:  1973-02

Review 6.  Antimicrobial therapy of infections due to anaerobic bacteria.

Authors:  V E Del Bene; W E Farrar
Journal:  Semin Drug Treat       Date:  1972

7.  Kinetics of the synergism of penicillin-streptomycin and penicillin-kanamycin for enterococci and its relationship to L-phase variants.

Authors:  W L Hewitt; S J Seligman; R A Deigh
Journal:  J Lab Clin Med       Date:  1966-05

8.  Synergism of cefazolin-gentamicin against enterococci.

Authors:  M Bourque; R Quintiliani; R C Tilton
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

9.  Cefamandole: in vitro and clinical pharmacokinetics.

Authors:  R S Griffith; H R Black; G L Brier; J D Wolny
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

10.  Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia.

Authors:  R J Weinstein; L S Young; W L Hewitt
Journal:  J Lab Clin Med       Date:  1975-11
View more
  5 in total

1.  Clinical comparison of antibiotic combinations in the treatment of peritonitis and related mixed aerobic-anaerobic surgical sepsis.

Authors:  H H Stone; T C Fabian
Journal:  World J Surg       Date:  1980-07       Impact factor: 3.352

2.  Effect of antibiotics on the prevention of experimental Bacteroides fragilis endocarditis.

Authors:  P L Goldman; D T Durack; R G Petersdorf
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

3.  Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to erythromycin.

Authors:  S L Hansen; P Swomley; G Drusano
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

4.  In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.

Authors:  J R Cohn; D L Jungkind; J S Baker
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

5.  In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Authors:  P B Fernandes; R Bailer; R Swanson; C W Hanson; E McDonald; N Ramer; D Hardy; N Shipkowitz; R R Bower; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.